Cresco Labs Inc.

Cresco Labs Inc., alongside its subsidiaries, is a prominent player in the United States' cannabis industry, handling the cultivation, production, and distribution of cannabis products for both recreational and medicinal markets. Their extensive product line encompasses various forms of cannabis. The Cresco brand offers flowers, vape pens, live resins, disposable pens, and extracts. High Supply provides vapes, different cannabis flower formats (like popcorn and shake), pre-rolls, and concentrates. Edibles and infused products are also a significant part of their portfolio, with Good News featuring vapes and gummies, and Wonder Wellness Co. offering vapes and edibles. For therapeutic applications, the Remedi brand includes tinctures, capsules, salves, and sublingual oils. Other cannabis offerings are available under the Reserve and FloraCal brands (the latter specializing in cannabis flowers). Their edibles selection further expands with Mindy's Edibles, which crafts chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy. Cresco Labs also holds a licensing agreement for the Kiva brand, known for its cannabis-infused edibles such as chocolates, gummies, mints, and tarts, and markets its own infused edibles under the Sunnyside brand. As of December 6, 2022, the company maintained a retail footprint of 55 operational dispensaries. Cresco Labs was founded in 2013 and has its corporate headquarters situated in Chicago, Illinois.

Cresco Labs Inc. trades as CL.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $667.33M of revenue and -$137.78M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Cresco Labs Inc. can be compared against peers such as Aurora Cannabis Inc., Cipher Pharmaceuticals Inc., Bright Minds Biosciences Inc., Knight Therapeutics Inc., MariMed Inc., OrganiGram Holdings Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $442.78M, beta of 1.71, and return on equity of -40.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CL.CN currently shows total debt of $583.10M and beta of 1.71. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.crescolabs.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.